Miller Value Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Miller Value Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,000	Closed	-$80K	–	143
2021 Q4	$80K	Hold	10,000	–	–	﹤0.01%	121
2021 Q3	$97K	Hold	10,000	–	–	﹤0.01%	119
2021 Q2	$99K	Hold	10,000	–	–	﹤0.01%	123
2021 Q1	$115K	Hold	10,000	–	–	﹤0.01%	109
2020 Q4	$97K	Buy	+10,000	New	+$95.8K	﹤0.01%	97
2020 Q1	–	Sell	-600,000	Closed	-$5.88M	–	87
2019 Q4	$5.88M	Hold	600,000	–	–	0.21%	54
2019 Q3	$4.13M	Buy	600,000 +100,000	+20%	+$766K	0.17%	58
2019 Q2	$4.62M	Buy	+500,000	New	+$6.03M	0.18%	55

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Miller Value Partners's TEVA Position: Q1 2025 in Review

Miller Value Partners sold out of Teva Pharmaceuticals (TEVA) in Q1 2025, closing a stake of 10,950 shares — an estimated $241K sold.

Miller Value Partners first reported a position in TEVA in Q4 2017 and held it in 29 quarters. The position peaked at $122M in Q1 2021. 560 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.

Miller Value Partners reported no remaining Teva Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Miller Value Partners sold 10,950 Teva Pharmaceuticals shares in Q1 2025, an estimated $241K.
Miller Value Partners first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 29 quarters.
Miller Value Partners's Teva Pharmaceuticals position peaked at $122M in Q1 2021.
560 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2025.

Based on Miller Value Partners's 13F filing for Q1 2025, filed 15 May 2025.